Outcomes of Patients With Autosomal Dominant Polycystic Kidney Disease Prescribed SGLT2 Inhibitors in British Columbia: A Single-Arm Retrospective Cohort Study

Alessandro Cau, Mark Elliott, Adeera Levin, Charith Karunarathna, Alexandra Romann, Ognjenka Djurdjev, Mohammad Atiquzzaman, Micheli Bevilacqua · 2025

Read Outcomes of Patients With Autosomal Dominant Polycystic Kidney Disease Prescribed SGLT2 Inhibitors in British Columbia: A Single-Arm Retrospective Cohort Study by Alessandro Cau, Mark Elliott, Adeera Levin, Charith Karunarathna, Alexandra Romann, Ognjenka Djurdjev, Mohammad Atiquzzaman, Micheli Bevilacqua (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12701218.txt.

Description

Alessandro Cau and co-authors review what happened when kidney cyst patients took a common diabetes drug class in this 2025 study. The disease is a leading cause of kidney failure, yet its patients were shut out of trials of these drugs over safety fears. Real-world data from British Columbia fills part of that gap.

The team reviewed charts for seventeen patients treated for a median of about twenty-one months. One patient met the mark for acute kidney injury while on the drug. A few saw an early dip in kidney function, and two had urinary infections that stayed mild. Average kidney decline did not worsen after starting. The authors stress the small size and lack of a comparison group.

Catalog record

CREATORAlessandro Cau, Mark Elliott, Adeera Levin, Charith Karunarathna, Alexandra Romann, Ognjenka Djurdjev, Mohammad Atiquzzaman, Micheli Bevilacqua
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE18 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12701218

Browse the full library · About the Tower of Babel